# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Mixed Connective Tissue Disease
- **MONDO ID:**  (if available)
- **Category:** Autoimmune

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Mixed Connective Tissue Disease**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2025-12-18T09:57:08.969653

1. carneromontoro2019epigenomewidecomparativestudy pages 1-2
2. ferrara2023towardsearlydiagnosis pages 2-4
3. hassan2023theprevalenceof pages 3-4
4. ferrara2023towardsearlydiagnosis pages 1-2
5. suwa2025transcriptomeanalysisunveils pages 1-4
6. ferrara2023towardsearlydiagnosis pages 9-10
7. suwa2025transcriptomeanalysisunveils pages 24-26
8. ciang2017mixedconnectivetissue pages 4-5
9. suwa2025transcriptomeanalysisunveils pages 11-17
10. 95% CI 8.30–18.48%
11. interquartile range (IQR) 1.54–3.91
12. 6.35% (IQR 4.17–17.49) vs 2.00% (IQR 1.20–2.80) P = 0.010
13. 95% CI 8.30-18.48%
14. {
      "id": "anti-U1_snRNP",
      "label": "Anti-U1 snRNP / U1-70K",
      "genes_HGNC": ["SNRNP70"
15. {"pqac":"(ferrara2023towardsearlydiagnosis pages 1-2)", "doi":"10.2147/itt.s390023", "year": 2023}
16. {"pqac":"(ferrara2023towardsearlydiagnosis pages 9-10)", "doi":"10.2147/itt.s390023", "year": 2023}
17. "IRF7","STAT1","MX1","IFI44L","PARP9","DDX60"
18. {"pqac":"(carneromontoro2019epigenomewidecomparativestudy pages 1-2)", "doi":"10.3389/fimmu.2019.01880", "year": 2019}
19. {"pqac":"(suwa2025transcriptomeanalysisunveils pages 1-4)", "doi":"10.1186/s13075-025-03707-4", "year": 2025}
20. {"pqac":"(izuka2025machinelearning–drivenimmunophenotypic pages 5-7)", "doi":"10.1093/rheumatology/keae158", "year": 2025}
21. {"pqac":"(ferrara2023towardsearlydiagnosis pages 2-4)", "doi":"10.2147/itt.s390023", "year": 2023}, {"pqac":"(ciang2017mixedconnectivetissue pages 4-5)", "doi":"10.1093/rheumatology/kew265", "year": 2017}
22. {"pqac":"(izuka2025machinelearning–drivenimmunophenotypic pages 5-7)", "doi":"10.1093/rheumatology/keae158", "year": 2025}, {"pqac":"(suwa2025transcriptomeanalysisunveils pages 1-4)", "doi":"10.1186/s13075-025-03707-4", "year": 2025}
23. {"label":"CD4+ Th1 cells", "CL":"Th1"},
    {"label":"Plasmablasts", "CL":"plasmablast"},
    {"label":"CD8+ central memory T cells", "CL":"CD8+ CM"},
    {"label":"Monocytes", "CL":"monocyte"},
    {"label":"Endothelial cells", "CL":"endothelial cell"},
    {"label":"Fibroblasts", "CL":"fibroblast"}
24. "Type I interferon signaling",
    "TGF-beta / SMAD signaling",
    "Epithelial–mesenchymal transition (EMT)",
    "IL-6 / JAK-STAT3",
    "NF-kB signaling",
    "Oxidative phosphorylation / metabolic reprogramming",
    "Reactive oxygen species (ROS) response"
25. {"label":"Interstitial lung disease","HP":"HP:0002835"},
    {"label":"Nonspecific interstitial pneumonia (NSIP)","HP":"HP:0002779"},
    {"label":"Usual interstitial pneumonia (UIP)","HP":"HP:0006505"},
    {"label":"Pulmonary arterial hypertension","HP":"HP:0002095"},
    {"label":"Raynaud's phenomenon","HP":"HP:0001822"},
    {"label":"Esophageal dysmotility","HP":"HP:0002031"},
    {"label":"Skin fibrosis","HP":"HP:0000954"}
26. {"label":"Lung","UBERON":"UBERON:0002048"},
    {"label":"Pulmonary artery","UBERON":"UBERON:0001004"},
    {"label":"Esophagus","UBERON":"UBERON:0001045"},
    {"label":"Skin","UBERON":"UBERON:0002097"}
27. {"pqac":"(ferrara2023towardsearlydiagnosis pages 2-4)", "doi":"10.2147/itt.s390023", "year": 2023}, {"pqac":"(hassan2023theprevalenceof pages 3-4)", "doi":"10.55563/clinexprheumatol/srma43", "year": 2023}
28. {"pqac":"(ferrara2023towardsearlydiagnosis pages 1-2)", "citation":"Ferrara CA et al., ImmunoTargets & Therapy", "doi":"10.2147/itt.s390023", "year": 2023},
    {"pqac":"(ferrara2023towardsearlydiagnosis pages 2-4)", "citation":"Ferrara CA et al. (extended)", "doi":"10.2147/itt.s390023", "year": 2023},
    {"pqac":"(carneromontoro2019epigenomewidecomparativestudy pages 1-2)", "citation":"Carnero-Montoro E et al., Front Immunol", "doi":"10.3389/fimmu.2019.01880", "year": 2019},
    {"pqac":"(hassan2023theprevalenceof pages 3-4)", "citation":"Hassan AB et al., Clin Exp Rheumatol (meta-analysis PAH)", "doi":"10.55563/clinexprheumatol/srma43", "year": 2023},
    {"pqac":"(izuka2025machinelearning–drivenimmunophenotypic pages 5-7)", "citation":"Izuka S et al., Rheumatology (immunophenotype)", "doi":"10.1093/rheumatology/keae158", "year": 2025},
    {"pqac":"(suwa2025transcriptomeanalysisunveils pages 1-4)", "citation":"Suwa Y et al., Arthritis Res Ther (Th1 signature)", "doi":"10.1186/s13075-025-03707-4", "year": 2025},
    {"pqac":"(ciang2017mixedconnectivetissue pages 4-5)", "citation":"Ciang NCO et al., Rheumatology (review)", "doi":"10.1093/rheumatology/kew265", "year": 2017}
29. https://doi.org/10.2147/itt.s390023
30. https://doi.org/10.3389/fimmu.2019.01880
31. https://doi.org/10.1186/s13075-025-03707-4
32. https://doi.org/10.1093/rheumatology/keae158
33. https://doi.org/10.55563/clinexprheumatol/srma43
34. https://schema.org",
35. https://doi.org/10.2147/itt.s390023,
36. https://doi.org/10.3389/fimmu.2019.01880,
37. https://doi.org/10.1186/s13075-025-03707-4,
38. https://doi.org/10.1093/rheumatology/keae158,
39. https://doi.org/10.55563/clinexprheumatol/srma43,
40. https://doi.org/10.1093/rheumatology/kew265,